TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Protein: The amino acid sequence has at least 80-95% sequence identity to SEQ ID NO. 2-7. A protein has a signature motif that aligns with a reference sequence SEQ ID NO. 2, the signature motif comprising Asn167, His168, Arg215, Tyr222 residues. Preferred Composition: The carrier is selected from a pharmaceutical carrier; an oral carrier; and a cosmetic carrier. The carrier comprises a polyol. The polyol is selected from a diol; a triol; and other alcohols containing multiple hydroxyl groups, and their combination. The polyol is selected from glycerin; glycerol; polyethylene glycol; polypropylene glycol; isomalt; lactitol; maltitol; mannitol; sorbitol; xylitol; and their combination. The polyol comprises glycerin. The carrier comprises a chelating agent selected from EDTA (preferred), citric acid; nitrolotriacetic acid; and phosphorus-acetic acid; and their combination. Preferred Method: In the method of producing a biofuel, the hydrolysate is derived from an extract of a seaweed selected from red algae, brown algae, green algae and their combination. The red algae comprises laver, agar-agar, sea string, and Grateloupiaceae, the brown algae comprises sea mustard, laminaria, seaweed fusiforme, gulfweed, Ecklonia siomnifera, rhubarb, and Potamogeton oxyphyllus, and the green algae comprises green laver, sea latnice, Monostroma nitidum, and sea staghorn. The extract comprises a red alga extract selected from among agar, cellulose, carrageenan, xylan, and mannan, a green alga extract selected from among cellulose, xylan, mannan, starch, fructan, and paramylon, or a brown alga extract selected from among cellulose, alginate, fucoidan and laminaran. The hydrolysate is a monosaccharide, a furan compound or an organic acid, where the hydrolysate comprises a compound selected from galactose, glucose, xylose, mannose and their combination when the extract from red algae is hydrolyzed, from glucose, xylose, mannose, fructose and their combination when the extract from green algae is hydrolyzed, or from glucose, glucuronic acid, fucose, galactose, xylose, mannitol and their combination when the extract from brown algae is hydrolyzed. The biofuel comprises an oxygen-containing compound or a biohydrocarbon, where the oxygen-containing compound is selected from ethanol, propanol, butanol, pentanol, hexanol and their combination, and where the biohydrocarbon is selected from biogasoline, biodiesel, a jet fuel, an additive and their combination. In the method of cleaning, disinfecting or sterilizing an inert surface, the inert surface is selected from a prosthetic device; a ventilator, a catheter and an intrauterine device. In the method of treating, preventing or inhibiting a disease, disorder or condition marked by an abnormal level of hyaluronic acid, administration of a protein comprising an amino acid sequence selected from SEQ ID NO. 2-7 inhibits tumor progression. Sequences not defined here may be found at ftp://ftp.wipo.int/pub/published_pct_sequences/publication. In the method of improving delivery of an intravenous composition, the subject is below the age of 18, preferably below the age of 12. ACTIVITY - Uropathic; Auditory; Antibacterial; Antiinflammatory; Ophthalmological; Cardiant; CNS-Gen; Respiratory-Gen; Cytostatic. Test details are described but no results given.    MECHANISM OF ACTION - Gene Therapy.    ADMINISTRATION - The composition may be adapted for oral, parenteral, sublingual, nasal or transdermal administration. No dosage details given.    EXAMPLE - No suitable example given.